FGP
ORIC icon

Freestone Grove Partners’s Oric Pharmaceuticals ORIC Stock Holding History

Freestone Grove Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,207
Closed -$198K – 1131
2025
Q4 		$198K Buy
+24,207
New +$279K ﹤0.01% 700

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Freestone Grove Partners's ORIC Position: Q1 2026 in Review

Freestone Grove Partners sold out of Oric Pharmaceuticals (ORIC) in Q1 2026, closing a stake of 24,207 shares — an estimated $198K sold.

Freestone Grove Partners first reported a position in ORIC in Q4 2025 and held it in 1 quarter. The position peaked at $198K in Q4 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Freestone Grove Partners reported no remaining Oric Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 24,207 Oric Pharmaceuticals shares in Q1 2026, an estimated $198K.
  • Freestone Grove Partners first reported a position in Oric Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Oric Pharmaceuticals position peaked at $198K in Q4 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.